Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Compugen Ltd. stock logo
CGEN
Compugen
$1.45
-2.0%
$1.60
$1.13
$2.66
$132.07M2.61265,927 shs96,988 shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$16.86
+5.6%
$11.74
$6.53
$26.40
$139.81M2.9126,564 shs208,903 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$1.52
-5.6%
$1.49
$0.89
$3.10
$121.00M-0.21847,167 shs933,668 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$0.80
-5.1%
$0.76
$0.66
$1.79
$32.98M1.64204,563 shs137,084 shs
10 Stocks Set to Soar in Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Compugen Ltd. stock logo
CGEN
Compugen
+0.68%+1.37%-6.92%+8.03%-15.43%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
+3.43%+15.89%+7.54%+115.52%-3.56%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
-1.83%+8.78%+13.38%-3.59%+54.81%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-1.72%+15.45%+3.19%-13.66%-51.15%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Compugen Ltd. stock logo
CGEN
Compugen
1.9471 of 5 stars
3.54.00.00.01.80.00.0
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3.0713 of 5 stars
2.91.00.04.62.00.80.0
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.6465 of 5 stars
3.53.00.00.03.41.71.9
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.9725 of 5 stars
0.04.00.00.02.60.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Compugen Ltd. stock logo
CGEN
Compugen
3.00
Buy$4.00175.86% Upside
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
1.75
Reduce$73.67336.93% Upside
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.00
Buy$15.00886.84% Upside
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Compugen Ltd. stock logo
CGEN
Compugen
$27.86M4.64N/AN/A$0.56 per share2.59
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$126.32M1.17N/AN/A$3.76 per share4.48
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$59.76M2.02$0.09 per share17.80$0.47 per share3.23
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$2.63M11.89N/AN/A$1.45 per share0.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Compugen Ltd. stock logo
CGEN
Compugen
-$14.23M-$0.22N/AN/AN/A-87.45%-34.77%-16.82%N/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$140K-$4.60N/AN/AN/AN/A-350.16%-67.69%N/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$8.31M$0.04N/A4.90N/A-21.03%-30.89%-11.74%N/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$21.29M-$0.40N/A16.03N/A-599.05%-41.02%-26.14%8/14/2025 (Estimated)

Latest SCYX, CGEN, PLX, and MCRB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.23-$0.14+$0.09-$0.14$0.15 million$1.36 million
8/6/2025Q2 2025
Compugen Ltd. stock logo
CGEN
Compugen
-$0.07-$0.08-$0.01-$0.08$3.95 million$1.26 million
8/6/2025Q2 2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$2.72-$2.27+$0.45-$2.27$11.75 millionN/A
5/19/2025Q1 2025
Compugen Ltd. stock logo
CGEN
Compugen
-$0.06-$0.08-$0.02-$0.08$3.70 million$2.28 million
5/15/2025Q1 2025
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.23-$0.17+$0.06-$0.11$0.14 million$0.26 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Compugen Ltd. stock logo
CGEN
Compugen
N/AN/AN/AN/AN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Compugen Ltd. stock logo
CGEN
Compugen
N/A
4.74
4.74
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/A
1.57
1.57
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A
1.98
1.27
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/A
5.83
5.83

Institutional Ownership

CompanyInstitutional Ownership
Compugen Ltd. stock logo
CGEN
Compugen
12.22%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
59.34%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
16.53%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
54.37%

Insider Ownership

CompanyInsider Ownership
Compugen Ltd. stock logo
CGEN
Compugen
9.50%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
4.70%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
6.50%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
4.86%
CompanyEmployeesShares OutstandingFree FloatOptionable
Compugen Ltd. stock logo
CGEN
Compugen
7089.24 million80.76 millionOptionable
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3308.75 million8.34 millionOptionable
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
20079.61 million69.00 millionOptionable
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
6039.02 million37.12 millionOptionable

Recent News About These Companies

Scynexis reports Q2 EPS (14c), consensus (19c)
SCYNEXIS (SCYX) to Release Quarterly Earnings on Thursday
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
Scynexis to present preclinical data on SCY-247 at ESCMID Meeting
SCYNEXIS Full Year 2024 Earnings: Misses Expectations
Maxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Compugen stock logo

Compugen NASDAQ:CGEN

$1.45 -0.03 (-2.03%)
Closing price 04:00 PM Eastern
Extended Trading
$1.44 0.00 (-0.34%)
As of 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Seres Therapeutics stock logo

Seres Therapeutics NASDAQ:MCRB

$16.86 +0.89 (+5.57%)
Closing price 04:00 PM Eastern
Extended Trading
$17.09 +0.23 (+1.36%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Protalix BioTherapeutics stock logo

Protalix BioTherapeutics NYSE:PLX

$1.52 -0.09 (-5.59%)
Closing price 04:00 PM Eastern
Extended Trading
$1.56 +0.03 (+2.30%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

SCYNEXIS stock logo

SCYNEXIS NASDAQ:SCYX

$0.80 -0.04 (-5.15%)
Closing price 04:00 PM Eastern
Extended Trading
$0.81 +0.01 (+1.42%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.